Peripherally Inserted Central Catheters Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Single Lumen, Double Lumen, and Triple Lumen), By Application (Therapeutics and Diagnostics), By End-User (Hospitals & Clinics, Homecare Setting, and Others), and Regional Forecast till 2032

A peripherally inserted central catheter (PICC) is a type of central line, also called a central venous catheter. The PICC line is a long, thin tube inserted into a deep vein of the upper arm. Patients can get medicine, fluids, blood, or nutrition through a PICC line. It also can be used to draw blood. There are several advantages of these products, such as peripherally inserted central catheters that can prevent pain that occurs due to frequent needle sticks and reduce the risk of irritation to smaller veins of arms. Additionally, these catheters can be used to obtain most blood tests and are used for many types of IV treatments.

The technological advancements in peripherally inserted central catheters and the launch of innovative catheters such as anti-thrombogenic and anti-microbial peripherally inserted central catheters are some of the factors that boost the global peripherally inserted central catheters market growth.

• In May 2023, Teleflex Incorporated launched two new PICC insertion devices. The two new devices, Arrow VPS Rhythm DLX and NaviCurve Stylet, would help enhance PICC insertion procedures and reduce complications. The introduction of a new positioning device and enhanced catheter design complement the company’s proprietary Arrowg+ard Blue Advance PICC anti-microbial and anti-thrombogenic protection. It reduces thrombus accumulation and the primary pathogens responsible for most healthcare-associated infections. These new devices can help to provide efficient PICC placement.

The growth of the global peripherally inserted central catheters (PICC) market is mainly driven by the increasing preference for the use of these catheters by physicians, increasing healthcare expenditure, and a growing number of diseases necessitating the application of peripherally inserted central catheters for disease treatment.

• As per data published by NCBI in June 2021, the use of PICCs can significantly increase the success rate of insertion and simultaneously decrease catheter-induced complications. Due to these factors, the use of PICCs in the treatment of various diseases has increased over the past few years.


• According to data provided by NCBI in September 2023, the PICC is a reliable and safe method for obtaining central venous access. These catheters are indicated for patients who need venous access for several weeks to months. In addition, they can be managed in inpatient and outpatient settings. They can be used for patients with limited peripheral access, long-term IV medication administration of antibiotics, patients with thrombocytopenia, and continuous administration of chemotherapeutic agents.

Thus, the various advantages offered by these catheters increase the usage and demand for the products, in turn driving the market growth.

Furthermore, peripherally inserted central catheters (PICCs) are frequently used for patients receiving chemotherapy. These catheters are also commonly used to deliver intravenous anti-microbial therapy for patients suffering from infectious diseases. Furthermore, PICCs are used in patients admitted to cardiac intensive care units. Hence, the rising prevalence of cardiovascular disease, cancer, and infectious diseases is anticipated to supplement the global peripherally inserted central catheters market growth by increasing the demand for the management of these diseases.

• As per the data provided by John Wiley & Sons, Inc. in February 2021, the worldwide incidence rate for all types of cancers combined was 222 per 100,000 in men and 186 per 100,000 in women for the year 2020.


• According to data provided by the Infection Prevention Society in April 2023, a majority of PICC insertions, 207 (77.8%), were performed between 2018 and 2021. The PICC insertion was most commonly done in chemotherapy, followed by prolonged antibiotic therapy.

Impact of COVID-19 on the Peripherally Inserted Central Catheters Market

During the COVID-19 pandemic, the peripherally inserted central catheters market faced a negative impact in 2020. This was due to decrease in hospital visits, for chronic diseases; lack of attention to infectious disease treatment programs; and surveillance efforts during the pandemic.

• According to data published by Anti-Microbial Resistance & Infection Control in June 2021, the COVID-19 spread led to a reduced attention to the traditional healthcare-associated infections (HAIs) prevention programs in terms of lack of surveillance efforts, process measures, and containment strategies.

The utilization of PICC for patients hospitalized with SARS-CoV-2 infection is associated with severe complications, ultimately decreasing the use of PICC during COVID-19.

• According to data published by NCBI in May 2023, many patients hospitalized with COVID-19 infection were potentially prone to other infectious complications. The use of PICC is associated with several complications, such as post-procedural hematoma, symptomatic CRT, and catheter-related infections.


• As per data published in the journal Annals of Palliative Medicine in November 2020, a study was conducted by incorporating 156 cancer patients who are PICCs treated at the cancer center. Out of 156 patients, 57 experienced delays in PICC care during COVID-19, and 12 suffered from complications, including infection, thrombosis, and mechanical failure.

The lack of focus on infection prevention programs and scarcity of PICCs negatively impacted the growth of the peripherally inserted central catheter market.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Chronic Diseases, By Key Countries/Regions, 2022


• New Product Launches, By Key Players


• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)


• Impact of COVID-19 on the Global Peripherally Inserted Central Catheters Market

Analysis by Product Type

Based on product type, the single-lumen segment accounted for a significant proportion of the peripherally inserted central catheters market in 2022. The growing use of single-lumen biomaterial PICC catheters and the increasing regulatory approvals for innovative products are some of the key factors that are responsible for segment growth.

• In March 2020, Access Vascular, Inc. received the U.S. FDA clearance for the second generation of its HydroPICC peripherally inserted central catheter. This product has demonstrated an average of 97% less thrombus accumulation on the catheter surface compared to other catheters, such as polyurethane catheters.


• As per the data provided by the Massachusetts Medical Society in January 2019, researchers from the Michigan academic medical center promoted the use of single-lumen as compared to multi-lumen PICC lines through a three-part quality improvement intervention. There is a relationship between the lumens count in peripherally inserted central catheter (PICC) lines and the risk for complications.

The cost-effectiveness of single-lumen catheters is additional factor driving the segmental expansion.

• As per data provided by Vascufirst in February 2021, the minimum number of catheter lumens is associated with a minimum risk of infection, thrombosis, and occlusion of the catheter. Compared to the use of other catheters with double or triple-lumen, the use of single-lumen PICCs would result in a cost saving of almost 10%.

Regional Analysis

To gain extensive insights into the market, Request for Customization

North America dominated the global peripherally inserted central catheters market in 2022 and is expected to maintain its position over the forecast period. The highest growth in the U.S. is due to the rising cancer burden and steadily growing geriatric population. The key reasons fueling the market growth are the established medical infrastructure and the easy availability of advanced diagnostic testing for a wide range of diseases. Additionally, the high prevalence of chronic diseases across the region is increasing the demand for peripherally inserted central catheters for the treatment of these diseases. This, in turn, is expected to propel the regional market growth.

• According to the American Cancer Society, Inc., cancer is Canada's primary cause of death and it is the second-leading cause of death, after heart disease, in the U.S. The lung cancer is the principal cause of cancer death in both sexes.


• In accordance with data published by Springer in January 2021, PICCs are inserted in more than 2.5 million people across the world annually in acute care facilities and around 5 million people in the U.S.

The increasing cases of chronic diseases and the utilization of PICCs at healthcare facilities in North America are driving the regional market expansion.

Key Players Covered

The report includes the profiles of key players including BD, AngioDynamics, B. Braun SE, Medtronic, Argon Medical Devices, Teleflex Incorporated, Access Vascular, Inc., and others.

Key Industry Developments

• In September 2023, Teleflex Incorporated announced that it had selected to exhibit Arrow VPS Rhythm DLX Device and Arrow PICCs preloaded with the NaviCurve Stylet at the Vizient Innovative Technology Exchange. The VPS Rhythm DLX Device and NaviCurve Stylet are designed to work together to give vascular access specialists more efficient and predictable PICC placement.


• In September 2022, B. Braun Medical Inc. announced the acquisition of the Clik-FIX catheter securement device portfolio from Starboard Medical, Inc. Devices covered under the acquisition included the Clik-FIX PICC/Central catheter securement device, Clik-FIX Neonatal PICC catheter securement device, and Clik-FIX Soft PICC/Central securement device.


• In January 2022, Dynamic Infusion Therapy, LLC, a provider of outsourced vascular access services, acquired Lifeline PICC, a company involved in providing high-quality services and supplies for peripherally inserted central catheters at healthcare organizations.


• In July 2020, iVascular announced the launch of its sergeant peripheral support catheter. The catheter is indicated for patients with peripheral artery disease in small vessels or challenging anatomy during diagnostic and interventional procedures.